O	O	O	0	14	Pentoxifylline	Pentoxifylline	B-NP	NN	O	0	ROOT	O
O	O	O	15	18	for	for	B-PP	IN	O	1	NMOD	O
O	O	O	19	22	the	the	B-NP	DT	O	4	NMOD	O
O	O	O	23	32	treatment	treatment	I-NP	NN	O	2	PMOD	O
O	O	O	33	35	of	of	B-PP	IN	O	4	NMOD	O
O	O	O	36	45	infection	infection	B-NP	NN	O	5	PMOD	O
O	O	O	46	50	with	with	B-PP	IN	O	4	NMOD	O
O	O	O	51	56	human	human	B-NP	JJ	O	10	NMOD	O
O	O	O	57	73	immunodeficiency	immunodeficiency	I-NP	NN	O	10	NMOD	O
O	O	O	74	79	virus	virus	I-NP	NN	O	7	PMOD	O
O	O	O	79	80	.	.	O	.	O	1	P	O

O	O	O	82	90	Cytokine	Cytokine	B-NP	NN	B-protein	2	NMOD	B-protein
O	O	O	91	104	dysregulation	dysregulation	I-NP	NN	O	14	NMOD	O
O	O	O	105	107	in	in	B-PP	IN	O	2	NMOD	O
O	O	O	108	113	human	human	B-NP	JJ	O	7	NMOD	O
O	O	O	114	130	immunodeficiency	immunodeficiency	I-NP	NN	O	7	NMOD	O
O	O	O	131	136	virus	virus	I-NP	NN	O	7	NMOD	O
O	O	O	137	141	type	type	I-NP	NN	O	3	PMOD	O
O	O	O	142	143	1	1	I-NP	CD	O	7	NMOD	O
O	O	O	144	145	(	(	O	(	O	13	DEP	O
O	O	O	145	148	HIV	HIV	B-NP	NN	O	12	SUB	O
O	O	O	148	149	-	-	B-NP	HYPH	O	12	P	O
O	O	O	149	150	1	1	I-NP	CD	O	13	DEP	O
O	O	O	150	151	)	)	O	)	O	2	NMOD	O
O	O	O	152	161	infection	infection	B-NP	NN	O	15	SUB	O
O	O	O	162	165	has	have	B-VP	VBZ	O	0	ROOT	O
O	O	O	166	170	been	be	I-VP	VBN	O	15	VC	O
O	O	O	171	181	documented	document	I-VP	VBN	O	16	VC	O
O	O	O	182	184	in	in	B-PP	IN	O	17	VMOD	O
O	O	O	185	193	numerous	numerous	B-NP	JJ	O	20	NMOD	O
O	O	O	194	201	studies	study	I-NP	NNS	O	18	PMOD	O
O	O	O	202	205	and	and	O	CC	O	15	VMOD	O
O	O	O	206	209	has	have	B-VP	VBZ	O	15	VMOD	O
O	O	O	210	214	been	be	I-VP	VBN	O	22	VC	O
O	O	O	215	220	cited	cite	I-VP	VBN	O	23	VC	O
O	O	O	221	223	as	as	B-PP	IN	O	24	VMOD	O
O	O	O	224	226	an	an	B-NP	DT	O	28	NMOD	O
O	O	O	227	236	important	important	I-NP	JJ	O	28	NMOD	O
O	O	O	237	246	component	component	I-NP	NN	O	25	PMOD	O
O	O	O	247	249	in	in	B-PP	IN	O	28	NMOD	O
O	O	O	250	253	the	the	B-NP	DT	O	31	NMOD	O
O	O	O	254	266	pathogenesis	pathogenesis	I-NP	NN	O	29	PMOD	O
O	O	O	267	269	of	of	B-PP	IN	O	31	NMOD	O
O	O	O	270	274	this	this	B-NP	DT	O	35	NMOD	O
O	O	O	275	285	retroviral	retroviral	I-NP	JJ	O	35	NMOD	O
O	O	O	286	295	infection	infection	I-NP	NN	O	32	PMOD	O
O	O	O	295	296	.	.	O	.	O	15	P	O

O	O	O	297	312	Pharmacological	Pharmacological	B-NP	JJ	O	2	NMOD	O
O	O	O	313	325	modification	modification	I-NP	NN	O	9	SUB	O
O	O	O	326	328	of	of	B-PP	IN	O	2	NMOD	O
O	O	O	329	337	cytokine	cytokine	B-NP	NN	B-protein	5	NMOD	B-protein
O	O	O	338	351	dysregulation	dysregulation	I-NP	NN	O	3	PMOD	O
O	O	O	351	352	,	,	O	,	O	9	P	O
O	O	O	353	362	therefore	therefore	B-ADVP	RB	O	9	VMOD	O
O	O	O	362	363	,	,	O	,	O	9	P	O
O	O	O	364	367	has	have	B-VP	VBZ	O	0	ROOT	O
O	O	O	368	372	been	be	I-VP	VBN	O	9	VC	O
O	O	O	373	382	suggested	suggest	I-VP	VBN	O	10	VC	O
O	O	O	383	385	as	as	B-PP	IN	O	11	VMOD	O
O	O	O	386	387	a	a	B-NP	DT	O	15	NMOD	O
O	O	O	388	399	therapeutic	therapeutic	I-NP	JJ	O	15	NMOD	O
O	O	O	400	408	modality	modality	I-NP	NN	O	12	PMOD	O
O	O	O	409	412	for	for	B-PP	IN	O	15	NMOD	O
O	O	O	413	416	HIV	HIV	B-NP	NN	O	20	NMOD	O
O	O	O	416	417	-	-	B-NP	HYPH	O	20	NMOD	O
O	O	O	417	418	1	1	I-NP	CD	O	20	NMOD	O
O	O	O	419	428	infection	infection	I-NP	NN	O	16	PMOD	O
O	O	O	428	429	.	.	O	.	O	9	P	O

O	O	O	430	432	Dr	Dr	B-NP	NNP	O	3	NMOD	O
O	O	O	432	433	.	.	I-NP	.	O	1	P	O
O	O	O	434	440	Dezube	Dezube	I-NP	NNP	O	12	SUB	O
O	O	O	441	443	of	of	B-PP	IN	O	3	NMOD	O
O	O	O	444	448	Beth	Beth	B-NP	NNP	O	7	NMOD	O
O	O	O	449	455	Israel	Israel	I-NP	NNP	O	7	NMOD	O
O	O	O	456	464	Hospital	Hospital	I-NP	NNP	O	4	PMOD	O
O	O	O	465	466	(	(	O	(	O	10	DEP	O
O	O	O	466	472	Boston	Boston	B-NP	NNP	O	10	DEP	O
O	O	O	472	473	)	)	O	)	O	7	NMOD	O
O	O	O	474	483	concisely	concisely	B-VP	RB	O	12	VMOD	O
O	O	O	484	491	reviews	review	I-VP	VBZ	O	0	ROOT	O
O	O	O	492	495	the	the	B-NP	DT	O	14	NMOD	O
O	O	O	496	501	state	state	I-NP	NN	O	12	OBJ	O
O	O	O	502	504	of	of	B-PP	IN	O	14	NMOD	O
O	O	O	505	508	our	our	B-NP	PRP$	O	17	NMOD	O
O	O	O	509	518	knowledge	knowledge	I-NP	NN	O	15	PMOD	O
O	O	O	519	528	regarding	regard	B-VP	VBG	O	17	NMOD	O
O	O	O	529	532	the	the	B-NP	DT	O	20	NMOD	O
O	O	O	533	540	effects	effect	I-NP	NNS	O	18	OBJ	O
O	O	O	541	543	of	of	B-PP	IN	O	20	NMOD	O
O	O	O	544	558	pentoxifylline	pentoxifylline	B-NP	NN	O	21	PMOD	O
O	O	O	559	561	on	on	B-PP	IN	O	20	NMOD	O
O	O	O	562	572	expression	expression	B-NP	NN	O	23	PMOD	O
O	O	O	573	575	of	of	B-PP	IN	O	24	NMOD	O
T1	B-Protein	B-Protein	576	581	tumor	tumor	B-NP	NN	B-protein	30	NMOD	B-protein
T1	I-Protein	I-Protein	582	590	necrosis	necrosis	I-NP	NN	I-protein	30	NMOD	I-protein
T1	I-Protein	I-Protein	591	597	factor	factor	I-NP	NN	I-protein	30	NMOD	I-protein
T1	I-Protein	I-Protein	597	598	-	-	O	HYPH	I-protein	30	P	I-protein
T1	I-Protein	I-Protein	598	603	alpha	alpha	B-NP	SYM	I-protein	33	NMOD	I-protein
O	O	O	603	604	,	,	O	,	O	33	P	O
O	O	O	605	606	a	a	B-NP	DT	O	33	NMOD	O
O	O	O	607	615	cytokine	cytokine	I-NP	NN	B-protein	25	PMOD	B-protein
O	O	O	616	621	known	know	B-VP	VBN	O	33	NMOD	O
O	O	O	622	624	to	to	I-VP	TO	O	36	VMOD	O
O	O	O	625	634	influence	influence	I-VP	VB	O	34	VMOD	O
O	O	O	635	638	HIV	HIV	B-NP	NN	O	40	NMOD	O
O	O	O	638	639	-	-	B-NP	HYPH	O	40	NMOD	O
O	O	O	639	640	1	1	I-NP	CD	O	40	NMOD	O
O	O	O	641	652	replication	replication	I-NP	NN	O	36	OBJ	O
O	O	O	653	656	and	and	O	CC	O	36	VMOD	O
O	O	O	657	659	to	to	B-VP	TO	O	43	VMOD	O
O	O	O	660	664	play	play	I-VP	VB	O	36	VMOD	O
O	O	O	665	666	a	a	B-NP	DT	O	46	NMOD	O
O	O	O	667	675	possible	possible	I-NP	JJ	O	46	NMOD	O
O	O	O	676	680	role	role	I-NP	NN	O	43	OBJ	O
O	O	O	681	683	in	in	B-PP	IN	O	43	VMOD	O
O	O	O	684	687	the	the	B-NP	DT	O	50	NMOD	O
O	O	O	688	696	clinical	clinical	I-NP	JJ	O	50	NMOD	O
O	O	O	697	711	manifestations	manifestation	I-NP	NNS	O	47	PMOD	O
O	O	O	712	714	of	of	B-PP	IN	O	50	NMOD	O
O	O	O	715	723	advanced	advanced	B-NP	JJ	O	53	NMOD	O
O	O	O	724	733	infection	infection	I-NP	NN	O	51	PMOD	O
O	O	O	734	738	with	with	B-PP	IN	O	53	NMOD	O
O	O	O	739	743	this	this	B-NP	DT	O	56	NMOD	O
O	O	O	744	749	virus	virus	I-NP	NN	O	54	PMOD	O
O	O	O	749	750	.	.	O	.	O	12	P	O

O	O	O	751	765	Pentoxifylline	Pentoxifylline	B-NP	NN	O	6	NMOD	O
O	O	O	765	766	,	,	O	,	O	6	P	O
O	O	O	767	768	a	a	B-NP	DT	O	6	NMOD	O
O	O	O	769	783	trisubstituted	trisubstitute	I-NP	VBN	O	6	NMOD	O
O	O	O	784	792	xanthine	xanthine	I-NP	NN	O	6	NMOD	O
O	O	O	793	803	derivative	derivative	I-NP	NN	O	8	SUB	O
O	O	O	803	804	,	,	O	,	O	6	P	O
O	O	O	805	808	has	have	B-VP	VBZ	O	0	ROOT	O
O	O	O	809	813	been	be	I-VP	VBN	O	8	VC	O
O	O	O	814	818	used	use	I-VP	VBN	O	9	VC	O
O	O	O	819	821	to	to	I-VP	TO	O	12	VMOD	O
O	O	O	822	830	decrease	decrease	I-VP	VB	O	10	VMOD	O
O	O	O	831	836	blood	blood	B-NP	NN	O	14	NMOD	O
O	O	O	837	846	viscosity	viscosity	I-NP	NN	O	12	OBJ	O
O	O	O	847	850	and	and	O	CC	O	8	VMOD	O
O	O	O	851	853	is	be	B-VP	VBZ	O	8	VMOD	O
O	O	O	854	864	reasonably	reasonably	I-VP	RB	O	19	VMOD	O
O	O	O	865	869	well	well	I-VP	RB	O	17	AMOD	O
O	O	O	870	879	tolerated	tolerate	I-VP	VBN	O	16	VC	O
O	O	O	880	882	by	by	B-PP	IN	O	19	VMOD	O
O	O	O	883	887	most	most	B-NP	JJS	O	22	NMOD	O
O	O	O	888	898	recipients	recipient	I-NP	NNS	O	20	PMOD	O
O	O	O	899	901	of	of	B-PP	IN	O	22	NMOD	O
O	O	O	902	905	the	the	B-NP	DT	O	25	NMOD	O
O	O	O	906	910	drug	drug	I-NP	NN	O	23	PMOD	O
O	O	O	910	911	.	.	O	.	O	8	P	O

O	O	O	912	919	Results	Result	B-NP	NNS	O	16	SUB	O
O	O	O	920	922	of	of	B-PP	IN	O	1	NMOD	O
O	O	O	923	934	preliminary	preliminary	B-NP	JJ	O	4	NMOD	O
O	O	O	935	942	studies	study	I-NP	NNS	O	2	PMOD	O
O	O	O	942	943	,	,	O	,	O	1	P	O
O	O	O	944	948	many	many	B-NP	JJ	O	7	NMOD	O
O	O	O	949	951	of	of	B-PP	IN	O	1	NMOD	O
O	O	O	952	957	which	which	B-NP	WDT	O	7	PMOD	O
O	O	O	958	962	were	be	B-VP	VBD	O	7	SBAR	O
O	O	O	963	972	conducted	conduct	I-VP	VBN	O	9	VC	O
O	O	O	973	975	by	by	B-PP	IN	O	10	VMOD	O
O	O	O	976	978	Dr	Dr	B-NP	NNP	O	14	NMOD	O
O	O	O	978	979	.	.	I-NP	.	O	14	P	O
O	O	O	980	986	Dezube	Dezube	I-NP	NNP	O	11	PMOD	O
O	O	O	986	987	,	,	O	,	O	1	P	O
O	O	O	988	995	suggest	suggest	B-VP	VBP	O	0	ROOT	O
O	O	O	996	1000	that	that	B-SBAR	IN	O	16	VMOD	O
O	O	O	1001	1004	use	use	B-NP	NN	O	27	SUB	O
O	O	O	1005	1007	of	of	B-PP	IN	O	18	NMOD	O
O	O	O	1008	1012	this	this	B-NP	DT	O	21	NMOD	O
O	O	O	1013	1018	agent	agent	I-NP	NN	O	19	PMOD	O
O	O	O	1019	1021	in	in	B-PP	IN	O	18	NMOD	O
O	O	O	1022	1033	combination	combination	B-NP	NN	O	22	PMOD	O
O	O	O	1034	1038	with	with	B-PP	IN	O	23	NMOD	O
O	O	O	1039	1053	antiretroviral	antiretroviral	B-NP	JJ	O	26	NMOD	O
O	O	O	1054	1063	compounds	compound	I-NP	NNS	O	24	PMOD	O
O	O	O	1064	1067	may	may	B-VP	MD	O	17	SBAR	O
O	O	O	1068	1073	prove	prove	I-VP	VB	O	27	VC	O
O	O	O	1074	1080	useful	useful	B-ADJP	JJ	O	28	PRD	O
O	O	O	1081	1083	in	in	B-PP	IN	O	29	AMOD	O
O	O	O	1084	1087	the	the	B-NP	DT	O	32	NMOD	O
O	O	O	1088	1097	treatment	treatment	I-NP	NN	O	30	PMOD	O
O	O	O	1098	1100	of	of	B-PP	IN	O	32	NMOD	O
O	O	O	1101	1109	patients	patient	B-NP	NNS	O	39	NMOD	O
O	O	O	1110	1114	with	with	B-PP	IN	O	34	NMOD	O
O	O	O	1115	1118	HIV	HIV	B-NP	NN	O	35	PMOD	O
O	O	O	1118	1119	-	-	B-NP	HYPH	O	34	P	O
O	O	O	1119	1120	1	1	I-NP	CD	O	39	NMOD	O
O	O	O	1121	1130	infection	infection	I-NP	NN	O	33	PMOD	O
O	O	O	1130	1131	.	.	O	.	O	16	P	O
